Carmen Parra-Cid

Dr. Carmen Parra-Cid

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2017 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
MMMarisol Maya-López
Marisol Maya-López
HRHipolito A. Ruiz-Contreras
Hipolito A. Ruiz-Contreras
MNMaría de Jesús Negrete-Ruíz
María de Jesús Negrete-Ruíz
Julián Elías Martínez-SánchezJulián Elías Martínez-Sánchez
Julián Elías Martínez-Sánchez
JBJuan Benítez-Valenzuela
Juan Benítez-Valenzuela
ASAbel Santamaria
Abel Santamaria

22 May 2013
Verified
Book Chapter
Open access
ZYZaira Y.
Zaira Y.
DGDavid Garciadiego-Czares
David Garciadiego-Czares
CPCarmen Parra-Cid
Carmen Parra-Cid
RARoco Aguilar-Gaytn
Roco Aguilar-Gaytn
CVCristina Velasquillo
Cristina Velasquillo
JCJavier S. Castro Carmo
Javier S. Castro Carmo

13 August 2021 in Neurochemical Research
Verified
Journal Article
Closed access
PDF file
LRLaura E. Ramos-Languren
Laura E. Ramos-Languren
AAAlberto Avila-Luna
Alberto Avila-Luna
GGGabriela García-Díaz
Gabriela García-Díaz
RLRoberto Rodriguez Labrada
Roberto Rodriguez Labrada
YVYaimee Vázquez-Mojena
Yaimee Vázquez-Mojena
RGRigoberto González-Piña
Rigoberto González-Piña

1 May 2014 in Neurotoxicology and Teratology
Verified
Journal Article
Closed access
CPCarmen Parra-Cid
Carmen Parra-Cid
JGJulieta García-López
Julieta García-López
EGEsperanza García
Esperanza García
CIClemente Ibarra
Clemente Ibarra

18 September 2009 in Macromolecular Symposia
Verified
Journal Article
Closed access
PDF file
Omar Felipe Fabela-SánchezOmar Felipe Fabela-Sánchez
Omar Felipe Fabela-Sánchez
DTDIANA ZARATE TRIVIÑO
DIANA ZARATE TRIVIÑO
EEE. A. Elizalde-Peña
E. A. Elizalde-Peña
ZGZ. García-Carvajal
Z. García-Carvajal
ISI. C. Sánchez
I. C. Sánchez
GLGabriel Luna-Barcenas
Gabriel Luna-Barcenas

17 June 2020 in CNS & Neurological Disorders - Drug Targets
Verified
Journal Article
Closed access
PDF file
CPCarmen Parra-Cid
Carmen Parra-Cid
EOEduardo Orozco-Castillo
Eduardo Orozco-Castillo
JGJulieta García-López
Julieta García-López
ECElena Contreras-Figueroa
Elena Contreras-Figueroa
LRLaura E. Ramos-Languren
Laura E. Ramos-Languren
ASAbel Santamaria
Abel Santamaria
Background: Parkinson’s Disease (PD) is a common neurodegenerative disorder affecting the dopaminergic (DAergic) system. Replacement therapy is a promising alternative aimed at reconstructing the cytoarchitecture of affected brain regions in PD. Experimental approaches, such as the replacement of DAergic neurons with cells obtained from the Enteric Nervous System (ENS) has yet to be explored. Objective: To establish and characterize a cell replacement strategy with ENS Cells (ENSCs) in a PD model in rats. Methods: Since ENSCs can develop mature DAergic phenotypes, here we cultured undifferentiated cells from the myenteric plexus of newborn rats, establishing that they exhibit multipotential characteristics. These cells were characterized and further implanted in the Substantia nigra pars compacta (SNpc) of adult rats previously lesioned by a retrograde degenerative model produced by intrastriatal injection of 6-Hydroxydopamine (6-OHDA). DAergic markers were assessed in implants to validate their viability and possible differentiation once implanted. Results: Cell cultures were viable, exhibited stem cell features and remained partially undifferentiated until the time of implant. The retrograde lesion induced by 6-OHDA produced DAergic denervation, reducing the number of fibers and cells in the SNpc. Implantation of ENSCs in the SNpc of 6-OHDAlesioned rats was tracked after 5 and 10 days post-implant. During that time, the implant increased selective neuronal and DAergic markers, Including Microtubule-Associated Protein 2 (MAP-2), Dopamine Transporter (DAT), and Tyrosine Hydroxylase (TH). Conclusion: Our novel results suggest that ENSCs possess a differentiating, proliferative and restorative potential that may offer therapeutic modalities to attenuate neurodegenerative events with the inherent demise of DAergic neurons.